指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

非静脉曲张性上消化道出血的内镜诊断与管理:欧洲胃肠道内镜学会(ESGE)指南2021年更新

Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021.
指南 / 共识 · Endoscopy · 2021-02-10
一句话结论ESGE指南推荐:急性上消化道出血用GBS评分行内镜前危险分层,GBS≤1者可安全门诊处理;血流动力学复苏后24小时内行早期内镜,不推荐12小时内紧急内镜。

该指南由欧洲胃肠道内镜学会(ESGE)制定,针对非静脉曲张性上消化道出血(NVUGIH)的内镜诊断与管理提出推荐。指南强调使用格拉斯哥-布拉奇福德评分(GBS)进行内镜前危险分层,GBS≤1者可在门诊安全处理;正在服用低剂量阿司匹林进行二级心血管预防的患者不应中断阿司匹林;血流动力学复苏后应行早期(≤24小时)内镜,不推荐紧急(≤12小时)内镜;对活动性出血溃疡(FIa、FIb)推荐肾上腺素注射联合第二种止血方式,对非出血可见血管(FIIa)推荐接触或非接触热疗、机械治疗或硬化剂注射单用或联合肾上腺素;内镜止血后及FIIb溃疡需高剂量PPI治疗,首选静脉推注后持续输注72小时。

要点

  • GBS≤1的急性上消化道出血患者再出血、30天死亡或需住院干预风险极低,可安全门诊内镜处理(强推荐,中等质量证据)。
  • 服用低剂量阿司匹林行二级心血管预防者不应中断阿司匹林;若中断应尽快重启,最好3-5天内(强推荐,中等质量证据)。
  • 血流动力学复苏后应行早期(≤24小时)内镜(强推荐,高质量证据);不推荐紧急(≤12小时)内镜,因与早期内镜相比患者结局未改善(强推荐,高质量证据)。
  • 活动性出血溃疡(FIa、FIb)推荐肾上腺素注射联合第二种止血方式(接触热疗或机械治疗)(强推荐,高质量证据)。
  • 内镜止血后及FIIb溃疡未内镜治疗者推荐高剂量PPI:静脉推注后持续输注(如80 mg后8 mg/h)72小时(强推荐,高质量证据)。

适用人群与场景

  • 急性上消化道出血(UGIH)患者,用于内镜前危险分层。
  • 服用低剂量阿司匹林作为二级心血管预防的急性UGIH患者。
  • 需要持续抗凝治疗的急性NVUGIH(如消化性溃疡出血)患者。

诊断标准与关键阈值

  • 格拉斯哥-布拉奇福德评分(GBS)≤1分:再出血、30天内死亡或需住院干预风险极低,可安全门诊内镜处理。

处置流程与药物剂量

  • 急性UGIH患者行内镜前GBS危险分层,GBS≤1者可门诊内镜处理。
  • 服用低剂量阿司匹林行二级心血管预防者不应中断阿司匹林;若中断应尽快重启,最好3-5天内。
  • 血流动力学复苏后行早期(≤24小时)上消化道内镜,不推荐紧急(≤12小时)内镜。
  • 活动性出血溃疡(FIa、FIb):肾上腺素注射联合第二种止血方式(接触热疗或机械治疗)。
  • 非出血可见血管(FIIa):接触或非接触热疗、机械治疗或硬化剂注射,各可单用或联合肾上腺素注射。
  • 标准止血方式难治的持续出血:可考虑局部止血喷雾/粉末或帽式夹。
  • 复发性消化性溃疡出血:可考虑帽式夹;第二次内镜止血失败可考虑经导管血管栓塞(TAE);TAE不可用或失败后行手术。
  • 内镜止血后及FIIb溃疡未内镜治疗者:高剂量PPI静脉推注后持续输注(如80 mg后8 mg/h)72小时;高剂量PPI静脉推注(每日两次)或口服(每日两次)可作为替代方案。

红旗征与不能漏的情况

  • 对标准止血方式难治的持续出血。
  • 临床证据提示复发性消化性溃疡出血。

研究设计与关键结果

  • 制定机构:欧洲胃肠道内镜学会(ESGE);方法:指南更新,采用推荐等级与证据质量分级体系。

证据类型、等级与局限

  • 指南,各推荐条款标注推荐强度与证据质量(强推荐/弱推荐;高质量/中等质量/低质量证据)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 急性UGIH患者内镜前应计算GBS,GBS≤1者可门诊内镜处理,避免不必要的住院。
  • 服用低剂量阿司匹林行二级心血管预防者不应中断阿司匹林;若中断应尽快重启,最好3-5天内。
  • 血流动力学复苏后行早期(≤24小时)内镜,不推荐紧急(≤12小时)内镜。
  • 活动性出血溃疡(FIa、FIb)采用肾上腺素注射联合第二种止血方式(接触热疗或机械治疗)。
  • 内镜止血后及FIIb溃疡未内镜治疗者给予高剂量PPI静脉推注后持续输注(如80 mg后8 mg/h)72小时。
  • 需持续抗凝者出血控制后尽快恢复抗凝,最好在出血事件7天内或之后不久,基于血栓栓塞风险。

指南或共识出处

  • Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021.

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

1: ESGE recommends in patients with acute upper gastrointestinal hemorrhage (UGIH) the use of the Glasgow-Blatchford Score (GBS) for pre-endoscopy risk stratification. Patients with GBS ≤ 1 are at very low risk of rebleeding, mortality within 30 days, or needing hospital-based intervention and can be safely managed as outpatients with outpatient endoscopy.Strong recommendation, moderate quality evidence. 2: ESGE recommends that in patients with acute UGIH who are taking low-dose aspirin as monotherapy for secondary cardiovascular prophylaxis, aspirin should not be interrupted. If for any reason it is interrupted, aspirin should be re-started as soon as possible, preferably within 3-5 days.Strong recommendation, moderate quality evidence. 3: ESGE recommends that following hemodynamic resuscitation, early (≤ 24 hours) upper gastrointestinal (GI) endoscopy should be performed. Strong recommendation, high quality evidence. 4: ESGE does not recommend urgent (≤ 12 hours) upper GI endoscopy since as compared to early endoscopy, patient outcomes are not improved. Strong recommendation, high quality evidence. 5: ESGE recommends for patients with actively bleeding ulcers (FIa, FIb), combination therapy using epinephrine injection plus a second hemostasis modality (contact thermal or mechanical therapy). Strong recommendation, high quality evidence. 6: ESGE recommends for patients with an ulcer with a nonbleeding visible vessel (FIIa), contact or noncontact thermal therapy, mechanical therapy, or injection of a sclerosing agent, each as monotherapy or in combination with epinephrine injection. Strong recommendation, high quality evidence. 7 : ESGE suggests that in patients with persistent bleeding refractory to standard hemostasis modalities, the use of a topical hemostatic spray/powder or cap-mounted clip should be considered. Weak recommendation, low quality evidence. 8: ESGE recommends that for patients with clinical evidence of recurrent peptic ulcer hemorrhage, use of a cap-mounted clip should be considered. In the case of failure of this second attempt at endoscopic hemostasis, transcatheter angiographic embolization (TAE) should be considered. Surgery is indicated when TAE is not locally available or after failed TAE. Strong recommendation, moderate quality evidence. 9: ESGE recommends high dose proton pump inhibitor (PPI) therapy for patients who receive endoscopic hemostasis and for patients with FIIb ulcer stigmata (adherent clot) not treated endoscopically. (A): PPI therapy should be administered as an intravenous bolus followed by continuous infusion (e. g., 80 mg then 8 mg/hour) for 72 hours post endoscopy. (B): High dose PPI therapies given as intravenous bolus dosing (twice-daily) or in oral formulation (twice-daily) can be considered as alternative regimens.Strong recommendation, high quality evidence. 10: ESGE recommends that in patients who require ongoing anticoagulation therapy following acute NVUGIH (e. g., peptic ulcer hemorrhage), anticoagulation should be resumed as soon as the bleeding has been controlled, preferably within or soon after 7 days of the bleeding event, based on thromboembolic risk. The rapid onset of action of direct oral anticoagulants (DOACS), as compared to vitamin K antagonists (VKAs), must be considered in this context.Strong recommendation, low quality evidence.

来源:Endoscopy,查看原文。版权归原作者所有。

参考来源

  1. Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. Endoscopy. 2021. PMID: 33567467. doi:10.1055/a-1369-5274

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。